Learn more about whether Jazz Pharmaceuticals plc or Johnson & Johnson is a better investment based on AAII's A+ Investor ...

Learn more about whether Bristol-Myers Squibb Company or Jazz Pharmaceuticals plc is a better investment based on AAII's A+ ...

Sei Investments Co. decreased its stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ – Free Report) by 30.5% in the 4th quarter, ...

Ultimately, Chimerix’s board went with Jazz’s offer due to its cash payable nature and the recent downward trend in biopharma ...

Jazz Pharmaceuticals is now committing $935 million to add this prospect to its pipeline. The drug, dordaviprone, was developed by Durham, North Carolina-based Chimerix. The cancer is H3 K27M ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

The deal is expected to close in the second quarter. Jazz Pharmaceuticals PLC will pay about $935 million cash to buy Chimerix Inc., a North Carolina company whose marquee drug for a type of ...

In this article, we are going to take a look at where Jazz Pharmaceuticals plc (NASDAQ:JAZZ) stands against the other best mid cap biotech stocks to buy. On March 6, Jared Holz, Mizuho health care ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will participate in the 24th Annual Needham Healthcare Conference. Company management will participate in a fireside chat on ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...